Demetrius Matassov, Ph.D.

Affiliations: 
2005 City University of New York, New York, NY, United States 
Area:
Cell Biology, Microbiology Biology
Google:
"Demetrius Matassov"

Parents

Sign in to add mentor
Zahra Zakeri grad student 2005 CUNY
 (Characterization and mechanism of influenza A virus induced cell death.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Eldridge JH, Egan MA, Matassov D, et al. (2021) A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses. Vaccine
Woolsey C, Jankeel A, Matassov D, et al. (2020) Immune correlates of postexposure vaccine protection against Marburg virus. Scientific Reports. 10: 3071
Clarke DK, Xu R, Matassov D, et al. (2020) Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. The Lancet. Infectious Diseases
Cross RW, Xu R, Matassov D, et al. (2019) Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. The Journal of Clinical Investigation
Woolsey C, Geisbert JB, Matassov D, et al. (2018) Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates. The Journal of Infectious Diseases
Matassov D, Mire CE, Latham T, et al. (2017) Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge. Journal of Virology
Nasar F, Matassov D, Seymour RL, et al. (2017) Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single dose protection against lethal alphavirus challenge. Journal of Virology
Matassov D, Marzi A, Latham T, et al. (2015) Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus. The Journal of Infectious Diseases. 212: S443-51
Mire CE, Matassov D, Geisbert JB, et al. (2015) Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature. 520: 688-91
Datan E, Shirazian A, Benjamin S, et al. (2014) MTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection Virology. 452: 175-190
See more...